THE GLP-1 FILES, PART 2: Will the Fat Even Stay?
July 29, 2026
AlloClae™™ is marketed as a source of ready-to-use, donor-derived volume. It is not a conventional filler or living fat transplant, and no one has directly...
Read More
July 29, 2026
AlloClae™™ is marketed as a source of ready-to-use, donor-derived volume. It is not a conventional filler or living fat transplant, and no one has directly...
Read More
July 22, 2026
There is a strange paradox taking shape in aesthetic medicine, predicated in large part by GLP-1 therapies for weight loss. No longer a niche treatment,...
Read More
July 8, 2026
A Higher Bar, A Wider Net: What ICH M14 and the New RWE Standards Mean for Medical Affairs In Part 1 of this series, we...
Read More
June 30, 2026
In the fall of 1960, a newly hired pharmacologist named Frances Kelsey received her first assignment at the FDA: review a drug called Kevadon [1]....
Read More
June 23, 2026
Do you ever wonder why pharmaceutical ads on Canadian TV stations are so radically different from US ads? That’s because Canada has distinctly different regulations,...
Read More